THE ANTITUMOR EFFECTS OF THE PRODRUGS N-L-LEUCYL-DOXORUBICIN AND VINBLASTINE-ISOLEUCINATE IN HUMAN OVARIAN-CANCER XENOGRAFTS

N-1-leucyl-doxorubicin and vinblastine-isoleucinate can be considered as relatively non-toxic prodrugs from doxorubicin and vinblastine, respectively. A comparative analysis was carried out of the anti-tumour activity of the four compounds as well as vintriptol in four human ovarian cancer xenografts different in histology, growth rate and chemosensitivity. Injections were given i.v. weekly twice into mice bearing well-established s.c. tumours. At equitoxic doses, the amount of drug administered for N4-leucyl-doxorubicin and vinblastine-isoleucinate was respectively 3-fold and 2-fold higher than the doses of the parent compound. N-1-leucyl-doxorubicin induced a growth inhibition >50% in three out of four human ovarian cancer lines. The anti-tumour effects obtained were significantly better (P<0.01) than in the caw of doxorubicin. Vinblastine-isoleucinate studied in two of these lines could induce a growth inhibition of >50%. This prodrug appeared slightly less effective than vinblastine. Insignificant growth inhibition (<50%) was obtained by vintriptol.